RHOA and gastric cancer: RHOA signaling also associated with cisplatin and docetaxel therapeutic actions in GC, in addition to association with miR-29, a regulator of both catenin-δ (CTNND1) and RHOA, implicating non-coding RNA epigenetic effects of chemotherapeutic agents (Wang et al., 2015).